(1.02%) 5 099.96 points
(0.40%) 38 240 points
(2.03%) 15 928 points
(0.11%) $83.66
(-1.16%) $1.619
(0.30%) $2 349.60
(-0.47%) $27.23
(0.41%) $924.25
(0.32%) $0.935
(0.80%) $11.04
(0.13%) $0.800
(-0.32%) $91.87
@ $9.81
Issued: 14 Feb 2024 @ 14:26
Return: -9.03%
Previous signal: Feb 14 - 09:30
Previous signal:
Return: 1.82 %
Live Chart Being Loaded With Signals
Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines to patients. Its registrational pipeline products include Lixivaptan, a vasopressin V2 receptor small molecule inhibitor that is in Phase III clinical development for the treatment of autosomal dominant polycystic kidney disease; and SerpinPC, an activated protein C inhibitor, which is in Phase IIa clinical development for the treatment of hemophilia A and B...
Stats | |
---|---|
Today's Volume | 254 924 |
Average Volume | 410 022 |
Market Cap | 881.07M |
EPS | $-0.400 ( 2023-11-13 ) |
Next earnings date | ( $-0.410 ) 2024-05-10 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -5.68 |
ATR14 | $0.0190 (0.21%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-03-31 | Chao David M | Sell | 10 385 | Ordinary Shares |
2024-03-31 | Weinhoff Gregory M | Sell | 11 742 | Ordinary Shares |
2024-03-31 | Saha Saurabh | Sell | 36 263 | Ordinary Shares |
2024-03-31 | Hussain Iqbal J | Sell | 7 520 | Ordinary Shares |
2024-03-31 | Bush Tia L | Sell | 6 419 | Ordinary Shares |
INSIDER POWER |
---|
61.97 |
Last 100 transactions |
Buy: 3 998 584 | Sell: 832 725 |
Volume Correlation
Centessa Pharmaceuticals Correlation
10 Most Positive Correlations | |
---|---|
UFPT | 0.914 |
TGAA | 0.912 |
RAMMU | 0.91 |
AMTBB | 0.907 |
PPSI | 0.904 |
TRON | 0.902 |
RDNT | 0.901 |
SKYW | 0.9 |
DFH | 0.899 |
NCAC | 0.898 |
10 Most Negative Correlations | |
---|---|
HYRE | -0.907 |
VIVE | -0.903 |
TLGT | -0.89 |
QTEK | -0.881 |
BVXV | -0.879 |
BHTG | -0.876 |
ONEM | -0.874 |
TRMT | -0.873 |
JG | -0.862 |
SVVC | -0.859 |
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Centessa Pharmaceuticals Correlation - Currency/Commodity
Centessa Pharmaceuticals Financials
Annual | 2023 |
Revenue: | $6.88M |
Gross Profit: | $6.07M (88.18 %) |
EPS: | $-1.580 |
FY | 2023 |
Revenue: | $6.88M |
Gross Profit: | $6.07M (88.18 %) |
EPS: | $-1.580 |
FY | 2022 |
Revenue: | $0 |
Gross Profit: | $-130 919 (0.00 %) |
EPS: | $-2.31 |
FY | 2021 |
Revenue: | $0.00 |
Gross Profit: | $0.00 (0.00 %) |
EPS: | $-4.05 |
Financial Reports:
No articles found.
Centessa Pharmaceuticals
Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines to patients. Its registrational pipeline products include Lixivaptan, a vasopressin V2 receptor small molecule inhibitor that is in Phase III clinical development for the treatment of autosomal dominant polycystic kidney disease; and SerpinPC, an activated protein C inhibitor, which is in Phase IIa clinical development for the treatment of hemophilia A and B. The company also has emerging pipeline products under clinical proof of concept stage comprising LB101, a PD-L1xCD47 LockBody, as well as LB201, a PD-L1xCD3 LockBody, which are designed to selectively drive potent CD47 and CD3 effector function activity while avoiding systemic toxicity; ZF874, a small molecule pharmacological chaperone folding corrector of the Z variant of alpha-1-antitrypsin in Phase I clinical development for the treatment of alpha-1-antitrypsin deficiency; MGX292, a recombinant modified BMP9 replacement protein designed to overcome the deficiency in BMP9 signaling in Pulmonary Arterial Hypertension; and OX2R Agonists that are oral and intranasal selective orexin receptor 2 agonists designed to leverage structural insights and to directly target the underlying pathophysiology of orexin neuron loss in Narcolepsy Type 1. In addition, the company has exploratory pipeline products under clinical proof of concept stage containing CBS001, an anti-LIGHT antibody, which preferentially binds the inflammatory membrane form of LIGHT in inflammatory/fibrotic diseases; and CBS004, a humanized mAb specific to BDCA2, expressed exclusively on plasmacytoid dendritic cells in systemic sclerosis, systemic lupus erythematosus, and other autoimmune diseases. Centessa Pharmaceuticals plc was incorporated in 2020 and is based in Altrincham, the United Kingdom.
About Live Signals
The live signals presented on this page help determine when to BUY or SELL NA. The signals have upwards of a 1-minute delay; like all market signals, there is a chance for error or mistakes.
The live trading signals are not definite, and getagraph.com hold no responsibility for any action taken upon these signals, as described in the Terms of Use. The signals are based on a wide range of technical analysis indicators